Omalizumab Improves Quality of Life (QoL) in Patients with Refractory Chronic Spontaneous/Idiopathic Urticaria (CSU/CIU) As Assessed By the Dermatology Life Quality Index (DLQI): A Post-Hoc Analysis of Percent Change from Baseline to Week 12

Omalizumab Improves Quality of Life (QoL) in Patients with Refractory Chronic Spontaneous/Idiopathic Urticaria (CSU/CIU) As Assessed By the Dermatology Life Quality Index (DLQI): A Post-Hoc Analysis of Percent Change from Baseline to Week 12

Rationale Omalizumab, an anti-IgE monoclonal antibody, was evaluated in three Phase III trials (ASTERIA-I/II and GLACIAL); we report DLQI data from all three studies.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of allergy and clinical immunology 2015-02, Vol.135 (2), p.AB127-AB127
Hauptverfasser: Rosén, Karin, MD, PhD, Khalil, Sam, PhD, Balp, Maria-Magdalena, MD, Maurer, Marcus, MD
Format: Artikel
Sprache:eng
Schlagworte:
Allergy and Immunology
Personal relationships
Quality of life
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Rationale Omalizumab, an anti-IgE monoclonal antibody, was evaluated in three Phase III trials (ASTERIA-I/II and GLACIAL); we report DLQI data from all three studies.
ISSN:0091-6749
1097-6825
DOI:10.1016/j.jaci.2014.12.1348